Penpulimab clinical trials
Also written AK105.
How each study uses penpulimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the penpulimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 23 Apr 2025 · PENPULIMAB-KCQX · BLA 761258 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
65 studies that test it; most in 2022 (23)
| Year | Studies |
|---|---|
| 2018 | 5 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 8 |
| 2022 | 23 |
| 2023 | 12 |
| 2024 | 7 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 27 · Other 38
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (16) · Akeso (8) · Peking Union Medical College Hospital (5) · The First Affiliated Hospital with Nanjing Medical University (4) · The First Affiliated Hospital of Zhengzhou University (3) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (3) · Hunan Cancer Hospital (2) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (2)
Often tested with
Tested in the same studies.
Anlotinib (25) · Catequentinib hydrochloride (11) · Anti-TIM-3 Monoclonal Antibody TQB2618 (4) · Disitamab vedotin (3) · Oxaliplatin (3) · Anti-LAG-3 Monoclonal Antibody TQB2223 (2) · Proteasome Inhibitor TQB3602 (1) · TQB2916 (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test penpulimab, phase 3 first.
- Dec 2026A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Phase 3 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Dec 2026Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCCPhase 2 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Studies
Open first, then newest update. How each study uses penpulimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 65
- R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS LymphomaNot yet recruitingNot applicableWEI XUNCT07764601Written as Penpulimab
- Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue SarcomaNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07612098Written as Penpulimab
- Clinical Studies for the Treatment of Advanced Solid TumorsRecruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06825494Written as LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine
- SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal CancerRecruitingPhase 2Ruijin HospitalNCT05576480Written as Penpulimab
- A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal AdenocarcinomaRecruitingPhase 2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06767800Written as TQB2102 for injection (6 mg/7.5 mg) +Penpulimab+Chemotherapy
- Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell CarcinomaRecruitingPhase 2Nanfang Hospital, Southern Medical UniversityNCT05214222Written as Anlotinib/Penpulimab/Chemotherapy
- A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell CarcinomaRecruitingPhase 2Lei LiuNCT06444009Written as Penpulimab combined with TP
- TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid TumorsNot yet recruitingPhase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06500091Written as TQB2916 injection+penpulimab injection
- Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung CancerRecruitingPhase 2The First Affiliated Hospital of Zhengzhou UniversityNCT06341530Written as anlotinib combined with penpulimab
- TQB2223 Injection in Combination With Penpulimab in Patients With Advanced CancersRecruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05894421Written as TQB2223 injection+ Penpulimab Injection
- Piamprilizumab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue SarcomaRecruitingNot applicableHenan Cancer HospitalNCT05718778Written as Piamprimab (AK105)
- A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological CancerRecruitingPhase 2Sichuan Cancer Hospital and Research InstituteNCT05028504Written as Penpulimab
- XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction AdenocarcinomaRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT05494060Written as Penpulimab Injection
- Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHNRecruitingPhase 2Eye & ENT Hospital of Fudan UniversityNCT05260671Written as Penpulimab combined with cetuximab
- Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid CancerNot yet recruitingNot applicablePeking Union Medical College HospitalNCT06062563Written as Anlotinib Hydrochloride Capsule and Penpulimab
- Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic CancerRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT06051851Written as Penpulimab
- The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic TreatmentRecruitingPhase 2Peking Union Medical College HospitalNCT05885399Written as Penpulimab
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05862337Written as Anlotinib hydrochloride capsules, Penpulimab injection
- A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial CarcinomaNot yet recruitingPhase 4Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05488353Written as Disitamab Vedotin for Injection,Penpulimab Injection
- Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System LymphomaNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT05347641Written as Penpulimab
See all 65 studies that test penpulimab →
Given beside what is tested · 7 — penpulimab is usual care or a partner of the new treatment
- A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell CarcinomaRecruitingPhase 2West China HospitalNCT07381075Written as Becotatug Vedotin Combined with Penpulimab
- Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort CRecruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06821503Written as Penpulimab injection
- JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment FailureNot yet recruitingPhase 1/2West China HospitalNCT07075419Written as Penpulimab
- A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06516978Written as Penpulimab
- Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRCRecruitingPhase 2Fudan UniversityNCT05229003Written as Penpulimab
- A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.RecruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06010901Written as Penpulimab injection
- A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal CarcinomaCompletedPhase 2AkesoNCT04736810Written as AK105
As the comparator · 2 — what is tested is compared with penpulimab
Codes
What other systems call penpulimab · ClinicalTrials.gg INT001779
- MeSH (NLM) C000720860penpulimabOne source NLM
- UNII (FDA) IBS1BZ4E4IPENPULIMABConfirmed FDA, NLM
- NCI Thesaurus C155879PenpulimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720860 | penpulimab | One source NLM |
| UNII (FDA) | IBS1BZ4E4I | PENPULIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C155879 | Penpulimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.